RESTENOZ KUZATILGAN BEMORLARNI OLIB BORISHDA MODERNIZATSIYALASHTIRILGAN ASPEKTLAR

##plugins.themes.academic_pro.article.sidebar##

Published Jun 17, 2023
Download
PDF
Statistic
Vol. 2 No. 6 (2023): Journal of Integrated Education and Research

##plugins.themes.academic_pro.article.main##

Nizomov X. Sh. , Kushnazarov R.S., Pulatov Sh.Sh., Ruziyeva A. A.
Respublika ixtisoslashgan kardiologiya ilmiy amaliy tibbiyot markazi Samarqand viloyat mintaqaviy filiali

Abstract

So'nggi 50 yil ichida dunyoning ko'plab mamlakatlari iqtisodiy jihatdan tez o'sishi va rivojlanishi bilan ajralib turdilar; bu ularni quyidagi guruhlarga bo'lish uchun asos bo'lib xizmat qildi: rivojlangan va rivojlanayotgan. Bu haqiqat hayot sharoitlarida yaxshi tomonga sezilarli o'zgarishlarga olib keladi va hayot sifatini to'g'ridan-to'g'ri nomutanosib ravishda oshiradi. O'z navbatida, aterosklerotik o'zgarishlarning paydo bo'lishiga olib keladigan omillar quyidagi turlarni ifodalaydi: nosog'lom turmush tarziga rioya qilish, xususan, nosog'lom ovqatlanish; arterial gipertenziyaning yuqori darajasi; gipodinamik ish va umuman turmush tarzi, chekish va yomon odatlar deb belgilangan boshqa barcha xavf omillari. Bularga yurak-qon tomir tizimining (YQT) aterosklerozi kiradi, bu koronar arteriya kasalligi (KAK) dan oldinroq bo'lgan. Aynan mana shu nozologiya dunyo mamlakatlarining o'lim va nogironlik darajasi yetakchisi vazifasini bajaradi [1,3,5]. Teri orqali koronar aralashuv (TOKA) saprning turli shakllarining terapevtik maqsadlari uchun eng keng tarqalgan, xususan, kardiovaskular sistemani (KVS)ni stentlash usuli sifatida, restenozlar sonining progressiv o'sishiga olib keladi, bu usul hozirgi vaqtda interventsion kardiologiyaning eng dolzarb muammosi hisoblanadi [2,4,7]. Pcidan keyin restenozning ishonchli aniqlangan chastotasi unchalik oson ish emas. Ko'pgina ishonchli manbalarda aytilishicha, koronar stentlar yaratilishidan oldingi davrda, balon angioplastikasi o'tkazilgandan so'ng, restenozning paydo bo'lish chastotasi 38-58% ga etadi.

##plugins.themes.academic_pro.article.details##

How to Cite
Nizomov X. Sh. , Kushnazarov R.S., Pulatov Sh.Sh., Ruziyeva A. A. (2023). RESTENOZ KUZATILGAN BEMORLARNI OLIB BORISHDA MODERNIZATSIYALASHTIRILGAN ASPEKTLAR . Journal of Integrated Education and Research, 2(6), 12–16. Retrieved from https://ojs.rmasav.com/index.php/ojs/article/view/1123

References

  1. World Health Organization. WHO Methods and data Sources for Country-Level Causes of Death 2000—2012.Geneva,Switzerland:WHO;2014.Accessed March 09, 2021.
  2. Byrne RA, Joner M, Kastrati A. Stent thrombosis and restenosis: what have we learned and where are we going? The Andreas Gruntzig Lecture ESC 2014. European Heart Journal. 2015;36(47):3320-3331.
  3. Fischman DL, Leon MB, Baim DS, Schatz RA, Savage MP, Penn I, Detre K, Veltri L, Ricci D, Nobuyoshi M. A randomized comparison of coronary-stent placement and balloon аngioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. The New England Journal of Medicine. 1994;331(8):496-501.
  4. Kirtane AJ, Gupta A, Iyengar S, Moses JW, Leon MB, Applegate R, Brodie B, Hannan E, Harjai K, Jensen LO, Park SJ, Perry R, Racz M, Saia F, Tu JV, Waksman R, Lansky AJ, Mehran R, Stone GW. Safety and efficacy of drug-eluting and bare metal stents: comprehensive meta-analysis of randomized trials and observational studies. Circulation. 2009;119(25):3198-3206.
  5. Cortese B, Berti S, Biondi-Zoccai G, Colombo A, Limbruno U, Bedogni F, Cremonesi A, Silva PL, Sgueglia GA; Italian Society of Interventional Cardiology. Drug-coated balloon treatment of coronary artery disease: a position paper of the Italian Society of Interventional Cardiology. Catheterization and Cardiovascular Interventions. 2014;83(3):427-435.
  6. Buccheri D, Piraino D, Andolina G, Cortese B. Understanding and managing in-stent restenosis: a review of clinical data, from pathogenesis to treatment. Journal of Thoracic Disease. 2016;8(10):1150-1162. https://doi.org/10.21037/jtd.2016.10.93
  7. Roubin GS, King SB III, Douglas JS Jr. Restenosis after percutaneous transluminal coronary angioplasty: the Emory University Hospital experience. The American Journal of Cardiology. 1987;60(3):39-43.
  8. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, Steg PG, Morel MA, Mauri L, Vranckx P, McFadden E, Lansky A, Hamon M, Krucoff MW, Serruys PW; Academic Research Consortium. Clinical end points in coronary stent trials: A case for standardized definitions. Circulation. 2007;115(17):2344-2351.
  9. Cassese S, Byrne RA, Schulz S, Hoppman P, Kreutzer J, Feuchtenberger A, Ibrahim T, Ott I, Fusaro M, Schunkert H, Laugwitz KL, Kastrati A. Prognostic role of restenosis in 10 004 patients undergoing routine control angiography after coronary stenting. European Heart Journal. 2015;36(2):94-99.
  10. Bossi I, Klersy C, Black AJ, Cortina R, Choussat R, Cassagneau B, Jordan C, Laborde JC, Laurent JP, Bernies M, Fajadet J, Marco J. In-stent restenosis: long-term outcome and predictors of subsequent target lesion revascularization after repeat balloon angioplasty. Journal of the American College of Cardiology. 2000;35(6):1569-1576.
  11. Nicolais C, Lakhter V, Virk HUH, Sardar P, Bavishi C, O’Murchu B, Chatterjee S. Therapeutic Options for In-Stent Restenosis. Current Cardiology Reports. 2018;20(2):7.
  12. Chen MS, John JM, Chew DP, Lee DS, Ellis SG, Bhatt DL. Bare metal stent restenosis is not a benign clinical entity. American Heart Journal. 2006;151(6):1260-1264.
  13. Dangas GD, Claessen BE, Caixeta A, Sanidas EA, Mintz GS, Mehran R. In-stent restenosis in the drug-eluting stent era. Journal of the American College of Cardiology. 2010;56(23):1897-1907.
  14. Magalhaes MA, Minha S, Chen F, Torguson R, Omar AF, Loh JP, Escarcega RO, Lipinski MJ, Baker NC, Kitabata H, Ota H, Suddath WO, Satler LF, Pichard AD, Waksman R. Clinical presentation and outcomes of coronary in-stent restenosis across 3-stent generations. Circulation. Cardiovascular Interventions. 2014;7(6):768-776.
  15. Агабабян, И. Р., Исмаилов, Ж. А., & Рузиева, А. А. (2020). Хроническая сердечная недостаточность у молодых пациентов с ожирением на фоне хронической обструктивной болезни легких. Достижения науки и образования, (3 (57)), 84-87.
  16. Пулатов, Ш. Ш., Рузиева, А. А., & Хасанжанова, Ф. О. (2023). Аспекты Кардиопротекции Пациентов Хронической Сердечной Недостаточности, Как Последствие Инфаркта Миокарда. Periodica Journal of Modern Philosophy, Social Sciences and Humanities, 17, 133-136.
  17. Низамов, Х. Ш., Рахматжановна, З., & Рузиева, А. А. (2023). Pandemic Features of Chronic Heart Failure in Young Patients. Periodica Journal of Modern Philosophy, Social Sciences and Humanities, 17, 155-158.
  18. Аскаров, И. К., Кушназаров, Р. С., Рузиева, А. А., & Хасанжанова, Ф. О. (2023). Предикторы Кардиопротекции Пациентов Хронической Сердечной Недостаточности, Как Последствие Инфаркта Миокарда. Periodica Journal of Modern Philosophy, Social Sciences and Humanities, 17, 137-140.